米妥莫单抗
化合物
米妥莫单抗（INN：Mitumomab；开发代号：BEC-2）是一种小鼠抗独特型（anti-idiotypic）单克隆抗体，研究用于与卡介苗疫苗联合治疗小细胞肺癌。米妥莫单抗攻击肿瘤细胞，而卡介苗被认为可以激活免疫系统。米妥莫单抗是由ImClone和默克公司开发的。[1]
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目標 | GD3神经节苷脂 |
| 臨床資料 | |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 216503-58-1  |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
第一个III期临床试验于1998年开始。[2][3]2005年和2008年两次发表的结果显示，接受米妥莫单抗和卡介苗治疗的患者没有获益。[4][5]
参见
编辑参考资料
编辑- ^ Mitumomab - AdisInsight. Adisinsight.springer.com. 2005-06-13 [2017-01-06]. （原始内容存档于2024-03-03）.
- ^ Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
- ^ Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
- ^ Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. European Journal of Cancer. October 2008, 44 (15): 2178–84. PMID 18676140. doi:10.1016/j.ejca.2008.06.036.
- ^ Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). Journal of Clinical Oncology. October 2005, 23 (28): 6854–64. PMID 16192577. doi:10.1200/JCO.2005.17.186
.
